Brief: Cymabay Therapeutics Reports Presentation Of Positive Results From Study Evaluating Seladelpar

CymaBay Therapeutics

16/11/2020 22:25

Nov 16 (Reuters) - Cymabay Therapeutics Inc  CBAY.O :
    * CYMABAY THERAPEUTICS ANNOUNCES ORAL LATE-BREAKING
PRESENTATION
OF POSITIVE RESULTS FROM THE ENHANCE GLOBAL PHASE 3 STUDY
EVALUATING SELADELPAR FOR PRIMARY BILIARY CHOLANGITIS AT THE
LIVER MEETING® 2020
    * CYMABAY THERAPEUTICS INC - RESULTS HIGHLIGHT POTENTIAL FOR
SELADELPAR TO OFFER PATIENTS AN EFFICACIOUS AND SAFE SECOND LINE
TREATMENT OPTION
    * CYMABAY THERAPEUTICS INC - GLOBAL 52-WEEK PHASE 3
REGISTRATION
STUDY (RESPONSE) TO BEGIN ENROLLING PATIENTS IN Q1 OF 2021
    * CYMABAY THERAPEUTICS INC - SELADELPAR DEMONSTRATED
ANTI-CHOLESTATIC, ANTI-INFLAMMATORY, AND ANTI-PRURITIC ACTIVITY
THROUGH 3 AND 6 MONTHS

Source text for Eikon:  ID:nGNX3qV4W8 
Further company coverage:  CBAY.O 

 ((Reuters.Briefs@thomsonreuters.com;))